Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- Gakkai, Specialty Certification and Industry by Mark Colby
September 10, 2007
- COMENTARY：Korosho Required to Cut \220 Bil. in Social Security Spending
September 3, 2007
- COMMENTARY／NHI Drug Pricing System Reform: Many Similarities in Proposals from JPMA, PhRMA, EFPIA
August 27, 2007
- COMMENTARY／Range of Drugs Re-priced due to Expansion of Market May Be Expanded
July 23, 2007
- COMMENTARY／Market for Osteoporosis Drugs Booms
July 9, 2007
- COMMENTARY／Pressure Mounting on Long-Listed Original Drugs
July 9, 2007
- COMMENTARY：Generic Firms Need Stronger Business Platform to Ensure Nationwide Stable Supply
June 25, 2007
- COMMENTARY／Provisional Deliveries without Agreement on Prices
June 11, 2007
- COMMENTARY／Show Road Map to the Goal - 30% Share for Generics
June 4, 2007
- COMMENTARY／Korosho to Consider Introduction of CU System
May 28, 2007
- Explosion of Shin-Etsu Chemical's Cellulose Production PlantGood Opportunity to Reconsider Raw Material Procurement System
April 30, 2007
- COMMENTARY／Japan Moves toward Affiliation with PIC/S
April 23, 2007
- COMMENTARY／India Attracts Increasing Attention of Japanese Pharmas
April 16, 2007
- COMMENTARY：Growing Market for Biopharmaceuticals
April 2, 2007
- Japanese Pharma Companies' Licensing Policy: 1 （2） Takeda Pharmaceutical Co., Ltd.
March 26, 2007
- Comentary
March 26, 2007
- Japanese Pharma Companies' Licensing Policy: 1 （1） Takeda Pharmaceutical Co., Ltd.
March 26, 2007
- Future of the Life Sciences Industries: Strategies for Success in 2015
March 19, 2007
- 3 Advantages of Gov't-Private Sector Dialogue Industry Needs to Continuously Present Proposals
February 19, 2007
- Breakthrough Pipelines of Japanese Pharma Companies Keiji Nakamura, Ph. D. Pharma Forum Institute, Kamakura 248-0026
February 12, 2007
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…